SOD3 and myocardial infarction: AAV9-mediated, cardiac-selective gene expression via systemic administration elevated EcSOD enzyme activity in the heart and provided protection against both acute MI and subsequent left ventricle remodeling along with increased myocardial capillary fractional area and decreased neutrophil infiltration, making systemic administration of AAV9-mediated it a viable gene therapy for MI [60].